Skip to content
CCF's 52nd Annual Chef's Tasting Logo

About the Crohn’s & Colitis Foundation

The mission of the Crohn's & Colitis Foundation is to cure Crohn's disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases.

INSPIRING AND ENGAGING PATIENTS/CAREGIVERS IN THE COUNTRY’S LARGEST IBD COMMUNITY

We bring together the largest community of IBD patients in the country, and we engage them in the fight against Crohn’s & colitis. Patients are involved in

  • Setting our research priorities
  • Contributing data and biosamples to accelerate research
  • Helping design our educational efforts alongside our scientific advisors, and
  • Advocating for key public policy issues to legislators

BUILDING RESILIENCY AND EMPOWERING PATIENTS

We are increasing support and education for our patients and caregivers in the effort to build resiliency and further empower them to take charge of their care, essential keys to wellness.

  • Live support groups
  • Web support groups
  • Camp Oasis
  • Shared decision-making programs

ACCELERATING THE PACE OF RESEARCH

We are accelerating research by breaking down traditional barriers to patients, data, funding, and collaborations. Specifically,

  • IBD Plexus: We have launched this large and unique database and biosample repository to enable our research partners to cut years off the research process.
  • IBD Ventures: We are investing in innovative products now in development by biotech companies and academics to significantly accelerate the pace of getting new treatments, devices, and diagnostic tools to clinicians and their patients.

LEVERAGING YEARS OF MAJOR, FOUNDATIONAL RESEARCH INVESTMENTS  

Our multi-year, multi-million-dollar research investments in areas that are important to IBD are paying off:

  • We are furthering Pediatric RISK study  findings to develop a test to predict disease severity at diagosis.
  • Microbiome–We are building on our early findings to develop therapeutic bacterial cocktails to treat IBD.
  • Genetics–We are now leveraging the extensive work we have done, in order to develop new drugs that target genetically controlled pathways in IBD.
 

CATALYZING CRITICAL RESEARCH IN NEW DOMAINS   

We are leading the way with millions of dollars of research investment in new, critically important areas of environmental disease triggers, such as diet and stress.

Invested more than $350 million into IBD research since our inception